Immuron (ASX:IMC): Clinical data imminent!
We spoke to Immuron CEO Steve Lydeamore about the clinical work it is doing with IMM-124e and IMM-529, its involvement with the Uniformed Services University and the Naval Medical Research Command, and the commercial opportunity for Travelan now that people are travelling again.